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ABSTRACT
Gestational diabetes is defined as impaired glucose tolerance with onset during
pregnancy and affects approximately 8.2% of pregnancies. Recently, it has been shown
that insulin resistance is a predictor of poor milk supply in women attempting to
breastfeed. Some mothers with gestational diabetes who used metformin for optimal
glycemic control during pregnancy have found that metformin use has improved their
ability to produce milk after delivery; however, the effects of continuing metformin
postpartum have not yet been studied. It is theorized that continued metformin use in the
postpartum period in women with gestational diabetes may improve postpartum milk
production. Using a randomized control trial, our objective is to determine if
continuing the use of metformin for 8 weeks postpartum is an effective intervention
in increasing milk supply in women who are diagnosed with gestational diabetes. We
hypothesize that we will see an increase in breast milk production in these women.

v

CHAPTER 1: INTRODUCTION
1.1 Background
1.1.1 The Burden of Gestational Diabetes Mellitus
Gestational diabetes mellitus (GDM) is one of the most common medical
complications of pregnancy and has important health implications for both the mother
and child even after pregnancy. In recent years, studies have shown that the rate of
mothers being diagnosed with GDM has significantly increased therefore making it an
important public health concern to address. In one study from 2016 it was estimated that
the prevalence of GDM increased to 8.2% from 4.6% in 2010. 1

Gestational diabetes mellitus is defined as impaired glucose tolerance with onset,
or first recognition, during pregnancy. 2 Insulin resistance during pregnancy stems from a
variety of factors, one being the secretion of human placental lactogen which is a
hormone that is produced and secreted by the placenta. This hormone functions in
breaking down fats from the mother in order to provide carbohydrates for the baby in the
placenta.3 Additionally, it creates a state of mild insulin resistance for the mother in order
to benefit the fetus by increasing the availability of maternal glucose for fetal
consumption.4 Normally, the beta cells of the pancreas are able to make additional insulin
to overcome this insulin resistance, but when the production of insulin is not enough to
overcome the effects of the placental hormones, the result is gestational diabetes.

Routine screening for GDM is typically performed been 24 and 28 weeks of
gestation and the diagnosis of GDM in the US is made using a series of tests, first a
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screen and then a diagnostic test. The first test is known as the oral glucose challenge test
(GCT).5 This test involves drinking a solution containing 50g of glucose and drawing
blood to measure glucose levels at one hour after consumption. If positive, women then
are asked to complete a fasting 3-hour oral glucose challenge test (OGTT) with 100g of
glucose in solution and have their glucose levels checked fasting and at 1, 2, and 3 hours
after consumption of the drink. There are two subtypes of gestational diabetes that are
classified using the White classification system, they are type A1 and type A2.3 A patient
is diagnosed with type A1 GDM if they are able to keep their blood sugars at goal with
diet and exercise alone. A diagnosis of type A2 GDM is made when a patient has GDM
and has blood glucose values above target for fasting and after meals. This type of GDM
requires more aggressive treatment with insulin or other medications.3

Gestational diabetes increases the risk of complications in pregnancy and
childbirth as well as long-term health for the mother and infant. GDM carries a long-term
risk of obesity and glucose intolerance in the offspring. One of the best interventions
proven to help reduce obesity in children is through breastfeeding, which is
recommended for the first six months of life according to the American Academy of
Pediatrics.6 However, only about 19% of women who initiate breastfeeding do so for the
entire six months.7 One of the biggest reasons that is given as to why many women stop
breastfeeding earlier than they intended to is because of a low milk supply. Other than
encouraging mothers to increase the frequency and thoroughness of breast emptying,
there are not any evidence-based strategies to help mothers increase their milk supply.8

2

Emerging evidence suggests that glucose intolerance and delayed lactogenesis are
correlated and that diabetes during pregnancy may increase the risk of persistent low milk
supply. In a case-control analysis, Riddle et al. 2016 showed that women who were
diagnosed with a low milk supply were significantly more likely to also have been
diagnosed with GDM and have problems with insulin metabolism compared to other
mothers.7 It has also been shown that lactation onset is delayed in obese women with
poor glucose control.9 The onset of lactation plays a crucial role in the duration of
breastfeeding as seen in a recent study by Chapman et al.10 This study additionally
showed that on average women who experienced delayed onset of lactation breastfed for
a much shorter duration.

Over time we have started to better understand that insulin plays a role in lactation
and that impaired insulin and glucose metabolism is correlated with poor lactation in
mothers. A recent study showed that insulin stimulates the expression of genes that are
directly involved in milk protein synthesis.11 Since proper insulin levels are necessary for
lactation, good glycemic control can enhance milk production while decreasing the delay
in lactation.12 We hypothesize that by continuing metformin postpartum in women who
were diagnosed with GDM and continuing to control glucose and insulin levels, we may
see an increase in breast milk production as well as a more rapid onset of lactation.
1.1.2 Role of Metformin Use in Gestational Diabetes Mellitus
It has been shown that with proper treatment of GDM the incidence of many of
the adverse complications associated with GDM can be reduced. Nutritional management
and exercise are the foundations of treatment, but insulin or metformin are added in
women who cannot achieve optimal glycemic control with diet and exercise changes
3

alone. Although insulin has been and still is considered the gold standard therapy of
choice during pregnancy for many decades, oral hypoglycemic medications have recently
been introduced as treatment for GDM as many women find the prospect of multiple
injections a day intolerable.13
One specific oral antidiabetic medication is metformin. This drug has been used
for decades in the treatment of type 2 diabetes as well as polycystic ovarian syndrome but
its use in pregnancy has be limited.14 Recently, several observational and randomized
control trials compared metformin to insulin and have found that metformin does not
increase adverse outcomes, and potentially even reduces maternal weight gain during
pregnancy, which is key in this population as many enter pregnancy with elevated
BMIs.15 Metformin has several mechanisms of action which include, decreasing hepatic
glucose production by suppressing gluconeogenesis, increasing insulin sensitivity, as well
as enhancing peripheral glucose uptake.14,16 All of these functions lead to lower blood
glucose levels and improved glycemic control.17 Since it is recently starting to be
understood that insulin plays a role in lactation and that impaired insulin and glucose
metabolism is correlated with poor lactation in mothers, we believe that by continuing
metformin during the postpartum period and continuing to control glucose levels, we
could see an increase in breast milk production as well as a more rapid onset of lactation.
In all of the studies that have addressed the different therapeutic options for
diabetes during pregnancy several neonatal and maternal outcomes have been analyzed
and studied but one factor that has not been studied in depth is the effect on breast milk
production and lactogenesis. Breastfeeding is an important factor that is known to impact
health outcomes in infancy and childhood making it an important factor to identify and
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study, especially in correlation with metformin therapy. It has been shown that delayed
onset of lactation and the perception of having a poor breastmilk supply is associated
with a shorter breastfeeding duration.10,18 Therefore, finding a way to increase the
postpartum milk production in women diagnosed with GDM could aid in longer
compliance with breastfeeding.
1.2 Statement of the Problem
For many years, it has been known that maternal obesity is associated with
delayed lactogenesis and a shortened duration of breastfeeding.19 Recently a study known
as the Feeding Practices Study II showed that “insufficient milk” was the primary factor
that mediated the association between maternal obesity and lower prevalence of exclusive
breastfeeding.20 We know that insulin resistance plays a huge role in obesity but for many
years it was believed that insulin did not play a direct role in mammary gland function.
Recently, studies have shown mammary glands to be sensitive to insulin during
pregnancy and lactation.21 This leads us to believe that mothers with insulin-resistant
conditions, such as gestational diabetes, are at an increased risk for insufficient milk
production.

Metformin is a first line drug for improving insulin sensitivity, and it is known to
be safe for use during lactation through studies of women with Type 2 diabetes;22
however, its efficacy in improving milk production has not yet been studied, specifically
when continuing treatment with metformin into the postpartum period in women
diagnosed with gestational diabetes and treated with metformin during pregnancy. This
supports the need for a randomized control trial to investigate the effects of metformin on
milk production. The results of this study could help shape best practices for
5

breastfeeding in mothers with gestational diabetes. It is relevant to medical practice,
specifically physician assistant practices, because it would aid in understanding how to
best treat mothers with gestational diabetes in the postpartum period and how to help
them reach their breastfeeding goals, which could in turn improve long-term health
outcomes for themselves as well as their children.

1.3 Goals and Objectives
This study aims to investigate the relationship between postpartum metformin use
and breastmilk production in women who were diagnosed with A2 gestational diabetes
and treated with metformin during pregnancy. We want to determine if metformin use
has an effect on the mammary glands and therefore milk production.

Our primary outcome will be breastmilk production which will be measured using
infant test weighs taken immediately before and after each feeding. This will be
statistically analyzed as a continuous variable. Secondary outcomes that will be measured
include the following: maternal fasting blood glucose levels, infant weight gain over the
course of the study period at office visits, number of wet diapers per day, and need for
supplementation with formula as prescribed by a pediatrician due to poor weight gain.
We have chosen these secondary variables because they are significant, independent
factors that may be predictors of how well our independent variable, metformin, is
functioning and the effects that it is producing in addition to how it affects maternal
glycemic control in the postpartum period. These outcomes will allow us to explore the
potential beneficial effects of metformin as an intervention on low milk supply in
mothers with gestational diabetes.

6

1.4 Hypothesis
We hypothesize that continuing metformin treatment for 8 weeks postpartum in women
who are diagnosed with gestational diabetes mellitus will lead to an increase in
breastmilk production through better glucose control.

1.5 Definitions
•

Blood Glucose Levels: The concentration of glucose present in the blood.
Measured with a sample of blood. A fasting blood glucose level under 100mg/dL
is normal in non-pregnant individuals.

•

Gestational Diabetes Mellitus: Gestational diabetes mellitus (GDM) occurs when
a woman’s pancreatic function is not sufficient to overcome the diabetogenic
environment of pregnancy. GDM is defined as glucose intolerance that was not
present or recognized prior to pregnancy.3

•

Insulin: A hormone made by the pancreas that allows your body to use sugar
(glucose) from carbohydrates in the food that you eat for energy or to store
glucose for future use. Insulin helps to prevent blood sugar level from getting too
high or too low.

•

Lactogenesis: The onset of milk secretion and includes all of the changes in the
mammary epithelium necessary to go from the undifferentiated mammary gland
in early pregnancy to full lactation.23

•

Metformin: Oral diabetes medication that helps control blood sugar levels.
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•

Postpartum: The period of time that begins immediately after the birth of a child
as the mother’s body returns to a non-pregnant state. In this study we refer to the
postpartum period as the first 8 weeks following childbirth.

8

1.6 References
1.

2.

3.
4.

5.
6.
7.
8.

9.

10.

11.

12.
13.
14.

15.

16.

ZHOU T, SUN D, LI X, et al. Prevalence and Trends in Gestational Diabetes
Mellitus among Women in the United States, 2006–2016. Diabetes.
2018;67(Supplement 1):121-OR.
Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and
management during and after pregnancy. Nat Rev Endocrinol. 2012;8(11):639649.
Gilmartin AB, Ural SH, Repke JT. Gestational diabetes mellitus. Rev Obstet
Gynecol. 2008;1(3):129-134.
Bhagavan NV. CHAPTER 34 - Endocrine Metabolism V: Reproductive System.
In: Bhagavan NV, ed. Medical Biochemistry (Fourth Edition). San Diego:
Academic Press; 2002:781-801.
Gupta Y, Kalra B. Screening and diagnosis of gestational diabetes mellitus. J Pak
Med Assoc. 2016;66(9 Suppl 1):S19-21.
Breastfeeding and the use of human milk. Pediatrics. 2012;129(3):e827-841.
Riddle SW, Nommsen-Rivers LA. A Case Control Study of Diabetes During
Pregnancy and Low Milk Supply. Breastfeed Med. 2016;11(2):80-85.
ABM Clinical Protocol #9: Use of galactogogues in initiating or augmenting the
rate of maternal milk secretion (First Revision January 2011). Breastfeed Med.
2011;6(1):41-49.
Nommsen-Rivers LA. Does Insulin Explain the Relation between Maternal
Obesity and Poor Lactation Outcomes? An Overview of the Literature. Adv Nutr.
2016;7(2):407-414.
Chapman DJ, Perez-Escamilla R. Does delayed perception of the onset of
lactation shorten breastfeeding duration? Journal of human lactation : official
journal of International Lactation Consultant Association. 1999;15(2):107-111;
quiz 137-109.
Menzies KK, Lee HJ, Lefèvre C, Ormandy CJ, Macmillan KL, Nicholas KR.
Insulin, a key regulator of hormone responsive milk protein synthesis during
lactogenesis in murine mammary explants. Funct Integr Genomics.
2010;10(1):87-95.
Insulin. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National
Library of Medicine (US); 2006.
Berggren EK, Boggess KA. Oral agents for the management of gestational
diabetes. Clin Obstet Gynecol. 2013;56(4):827-836.
Romero R, Erez O, Huttemann M, et al. Metformin, the aspirin of the 21st
century: its role in gestational diabetes mellitus, prevention of preeclampsia and
cancer, and the promotion of longevity. Am J Obstet Gynecol. 2017;217(3):282302.
Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus
Insulin for the Treatment of Gestational Diabetes. New England Journal of
Medicine. 2008;358(19):2003-2015.
Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin.
Diabetologia. 2017;60(9):1577-1585.
9

17.

18.

19.

20.

21.

22.
23.

Koffert JP, Mikkola K, Virtanen KA, et al. Metformin treatment significantly
enhances intestinal glucose uptake in patients with type 2 diabetes: Results from a
randomized clinical trial. Diabetes Res Clin Pract. 2017;131:208-216.
Li R, Fein SB, Chen J, Grummer-Strawn LM. Why mothers stop breastfeeding:
mothers' self-reported reasons for stopping during the first year. Pediatrics.
2008;122 Suppl 2:S69-76.
Nommsen-Rivers LA, Chantry CJ, Peerson JM, Cohen RJ, Dewey KG. Delayed
onset of lactogenesis among first-time mothers is related to maternal obesity and
factors associated with ineffective breastfeeding. Am J Clin Nutr. 2010;92(3):574584.
O'Sullivan EJ, Perrine CG, Rasmussen KM. Early Breastfeeding Problems
Mediate the Negative Association between Maternal Obesity and Exclusive
Breastfeeding at 1 and 2 Months Postpartum. J Nutr. 2015;145(10):2369-2378.
Lemay DG, Ballard OA, Hughes MA, Morrow AL, Horseman ND, NommsenRivers LA. RNA sequencing of the human milk fat layer transcriptome reveals
distinct gene expression profiles at three stages of lactation. PLoS One.
2013;8(7):e67531.
Priya G, Kalra S. Metformin in the management of diabetes during pregnancy and
lactation. Drugs Context. 2018;7:212523.
Neville MC, Morton J, Umemura S. Lactogenesis: The Transition from
Pregnancy to Lactation. Pediatric Clinics. 2001;48(1):35-52.

10

CHAPTER 2: REVIEW OF THE LITERATURE
2.1 Introduction
We conducted multiple searches of medical literature databases, including
PubMed, Ovid, and Cochrane, starting in August 2019 through July 2020. In these
searches, we used the MeSH terms [gestational diabetes] or [insulin resistance,
pregnancy-induced] and [metformin] or [hypoglycemic drugs] and [breast feeding] or
[lactation] or [human milk] or [milk supply]. We further reviewed the references of these
studies to identify relevant studies not found in our searches. We included mostly
systematic reviews, meta-analyses, and quantitative studies, including case-control
studies, cohorts, and randomized controlled trials.
2.2 Review of Empirical Studies
2.2.1 Gestational Diabetes Mellitus
Gestational diabetes mellitus (GDM), the most common metabolic disorder of
pregnancy, is defined as “the type of glucose intolerance that develops in the second and
third trimester of pregnancy, resulting in hyperglycemia of variable severity”1.
Gestational diabetes mellitus affects approximately 8.2% of pregnancies in the United
States, and it is increasing in prevalence as a consequence of increases in obesity
prevalence and advanced maternal age.2 Gestational diabetes mellitus occurs when a
mother develops dysglycemia because of endocrine disruption that occurs during
pregnancy. Insulin resistance during pregnancy stems from a variety of factors, one being
the secretion of human placental lactogen which is a hormone that is produced and
secreted by the placenta. This hormone functions in breaking down fats from the mother
in order to provide glucose for the baby in the placenta.3 Additionally, it creates a state of
11

mild insulin resistance for the mother in order to benefit the fetus by increasing the
availability of maternal glucose for fetal consumption.4 Normally, the beta cells of the
pancreas are able to make additional insulin to overcome this insulin resistance, but when
the production is insulin is not enough to overcome the effects of the placental hormones,
the result is gestational diabetes.

There are two different subtypes of gestational diabetes based on the White
Classification system; A1 and A2. They differ in the forms of treatment that they require.
Type A1 is able to be adequately controlled with diet and exercise whereas type A2
requires more intensive treatment with medications.5 Screening for GDM usually occurs
between 24 and 28 weeks of gestation6 and is typically done by utilizing the two step
approach. The first is a screening involving a 50g oral glucose challenge test, where the
mother drinks a beverage consisting of 50 grams of dissolved sugar and an hour later her
blood is drawn to measure the glucose concentration.6 If the value is less than 130-140
(depending on the lab and cut-off used) then the test is said to be normal, but if the blood
sugar levels are elevated then further testing must be conducted to diagnose gestational
diabetes.7 The subsequent diagnostic test to be performed is the glucose tolerance test
which must be done after the conclusion of an eight-hour fast by the patient. A fasting
sample of blood is taken first, typically first thing in the morning, and then the patient
drinks a beverage that contains 100 grams of glucose. Blood samples are then taken after
1, 2 and 3 hours.6 If two of the four blood sugar values are elevated the mother is then
diagnosed with GDM.8
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Once the diagnosis is made it is important to determine the best treatment plan
due to the risk of complications that are associated with it. The initial treatment of GDM
consists of diet modifications, glucose monitoring, and exercise. 9 If these measures fail
to adequately control blood sugar, medications such as insulin or metformin are used to
achieve euglycemia.6 Initiation of treatment in mothers with GDM is important because it
has been shown to reduce the rate of serious neonatal outcomes such as death, large for
gestational age infants, shoulder dystocia, bone fractures and nerve palsy.10

2.2.2 Treatment of Gestational Diabetes Mellitus
Insulin, for many years, has been the treatment of choice when lifestyle changes
fail to maintain proper glycemic control during pregnancy. 9 Recently studies have
suggested that oral hypoglycemic medications may be safe and acceptable alternatives,
one specific medication being metformin.11 Metformin was first approved for the
treatment of diabetes in the United States by the FDA in 1995 and has been used for
decades in the treatment of type 2 diabetes as well as polycystic ovarian syndrome but its
use in pregnancy has be limited.12 Metformin is a biguanide and has several mechanisms
of action which include, decreasing hepatic glucose production by suppressing
gluconeogenesis, increasing insulin sensitivity, as well as enhancing peripheral glucose
uptake.12 All of these functions lead to lower blood glucose levels and better glucose
control. Studies has shown that metformin can achieve blood glucose control in women
with GDM just as effectively as insulin but at a lower cost and with better adherence due
to it being an oral medication rather than one that must be injected.13 Additionally, one
randomized control trial known as the Metformin in Gestational Diabetes Trial which
was conducted by Rowan et al., compared the use of metformin to insulin in pregnant
13

women with GDM and found that metformin does not increase adverse outcomes and
may even reduce maternal weight gain during pregnancy.14 This was one of the largest
studies that aided in introducing metformin as an alternative treatment for GDM. When
treating women with gestational diabetes metformin can be initiated from the time of
diagnosis and is typically discontinued with delivery.

Although the standard therapy for women with gestational diabetes requiring drug
treatment has been insulin for many years, in some settings oral agents are now becoming
the first option.15 Metformin treatment is usually initiated with divided doses of 500mg
twice a day and the dose can be increased up to 2000mg daily.16 Oral agents are
becoming an attractive alternative to insulin due to their lower cost, easier administration
and better acceptance by patients compared to injections with insulin.

2.2.3 Benefits of Breastfeeding

Breastfeeding has many health benefits, both in the short term and long term for
both infants and their mothers. Due to ethical considerations it is difficult to perform
randomized control trials looking at the benefits of breastfeeding, but there have been
many observational studies that have carefully analyzed the relationship between
breastfeeding and maternal and infant outcomes. Research suggests there are particular
benefits of breastfeeding for women with a history of GDM and their infants,17 including
improved short-term insulin sensitivity and glucose homeostasis,18 improved long-term
insulin sensitivity,19 and reduced risk of type 2 diabetes20 many years postpartum.
Specifically, it was shown that women with GDM who breastfed for at least 3 months
had the lowest risk of development of diabetes after pregnancy.21 Some studies have
14

reported a protective association between breastfeeding and type 2 diabetes risk22,23 and
slower early weight gain24 among offspring of women with GDM. A systemic review by
the World Health Organization found that breastfed infants were 35% less likely to
develop subsequent type 2 diabetes compared to their non-breastfed
counterparts.25Despite established benefits of breastfeeding, there is evidence that
breastfeeding initiation, duration, and exclusivity may be lower among women with
GDM26-28
2.2.4 Relationship between Metabolic Disorders and Lactation
It is well established that obese women are at increased risk of delayed
lactogenesis and short breastfeeding duration, but the underlying causal contributors
remain unclear.29 Maternal obesity is a strong risk factor for insulin resistance and
prediabetes, but until recently a direct role for insulin in milk production had not been
elucidated. Over the past six years, studies in both animal models and humans have
shown insulin-sensitive gene expression to be dramatically upregulated specifically
during the lactation cycle. Insulin is now considered to play a direct role in lactation,
including essential roles in secretory differentiation, secretory activation, and mature milk
production. At the same time, emerging clinical research suggests an important
association between suboptimal glucose tolerance and lactation difficulty. To develop
effective interventions to support lactation success in obese women further research is
needed to identify how, when, and for whom maternal insulin secretion and sensitivity
affect lactation ability.
Recently there has been emerging evidence that suggests that glucose intolerance
and delayed lactogenesis are correlated and that diabetes during pregnancy may increase
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the risk of persistent low milk supply. In a case-control analysis it was shown that women
who were diagnosed with a low milk supply were significantly more likely to also have
been diagnosed with GDM. Specifically, they were found to be 2.6 times more likely to
have problems with insulin metabolism compared to other mothers.30 It has also been
shown that lactation onset is delayed in women with poor glucose control. The onset of
lactation plays a crucial role in the duration of breastfeeding as seen in a recent study by
Chapman et al.31 This studied showed that on average women who experienced delayed
onset of lactation, >72 hours after delivery, on average breastfed for 8 months less than
mothers who experienced lactation within 72 hours of delivery.
Although it’s been shown in studies that all women with GDM have lower
exclusive breastfeeding rates compared to women without GDM, one study which looked
at metformin versus placebo in postpartum women with GDM found that women who
had been randomized to the metformin group had a higher exclusive breastfeeding rate
compared to placebo, 22.2% versus 9.3%, p=0.055.32 This same study also found that the
frequency of breastfeeding cessation was lower in the metformin group compared to
placebo, 21.9% vs. 36.8%, p=0.912. In numerous studies it is frequently cited that low
milk supply is the reason why many mothers stop breastfeeding earlier than they had
planned.33 Riddle and Nommsen-Rivers (2016) conducted a case control study to better
understand the relationship between maternal diabetes and low milk supply, this was the
first study conducted to look at this relationship. The study found that the presence of
diabetes during pregnancy increased the risk of persistent low milk supply. Mothers with
a diagnosis of low milk supply but no other lactation problems, such as latching onto the
breast, were compared to mothers with lactation problems but without low milk supply.
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In the case group 14.9% of the women had a history of diabetes during pregnancy, while
in the control group 6.2% of the women who had lactation problems but not low milk
supply had maternal diabetes.30
Since low milk supply appears to be associated with gestational diabetes this
could support the concept that interventions targeting insulin action and glycemic control
may be a promising and novel strategy toward improving milk supply in vulnerable
mothers.
2.2.5 Breastfeeding Outcomes and Gestational Diabetes Mellitus
Studies of gestational diabetes mellitus in relation to breastfeeding are limited in
number but the majority suggest the same outcomes, that breastfeeding issues are higher
in mothers with GDM compared to mothers without GDM. These studies cite problems
such as delayed onset of lactation, lower breastmilk production and shorter breastfeeding
duration as some of the adverse outcomes from having GDM.30,31 Infants born to mothers
with GDM are more likely to experience complications, such as cesarean delivery,
preterm birth and macrosomia, and therefore require intensive care. All of these factors
also result in lower breastfeeding rates.34 In a U.S. study, women with GDM were about
40% less likely to be exclusively breastfeeding on hospital discharge compared women
without diabetes.27 In another study that covered 37 states in the United States, the
initiation rates were similar between mothers with and without GDM, but the mothers
with GDM tended to cease breastfeeding earlier: 65.7% vs 68.8% at 2 months
postpartum, respectively.35 Factors that may affect the disparity include physiologic and
behavioral challenges like higher prevalence of delayed onset of lactation,36,37 neonatal
hypoglycemia,38 breastfeeding problems at home, and inadequate breastfeeding.39
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Identification of a lower breastfeeding rate in a population that benefits more from
breastfeeding is what has motivated us to develop this research question to identify the
barriers that contribute to decreased breastfeeding in women with GDM. We hope to use
this study to determine proper methods and therapies to help combat these impediments
to breastfeeding. Additionally, we recognize the need to perform this study in a racially
and ethnically diverse population as these are populations with lower breastfeeding rates
and with higher risk for GDM.
2.3 Confounding Variables
It is difficult to isolate the effect of metformin on breastmilk production due to a
multitude of potential confounding variables. These include maternal age, maternal
ethnicity, maternal marital status, pre-pregnancy BMI, family history of GDM or type 2
diabetes, diagnosis of GDM in previous pregnancies, other signs of insulin resistance
such as polycystic ovarian syndrome or metabolic syndrome, number of previous
breastfed infants, vaginal versus cesarean delivery, gestational age at delivery, previous
breast surgery, maternal education level, maternal socioeconomic status and parity. The
majority of these will be discussed in this section.
Pre-pregnancy BMI is often controlled for in statistical analyses as a covariate in
studies that analyze the effect of GDM on breastfeeding.29 Most of these studies have
even found that pre-pregnancy BMI significantly affect their results.21,29. In a study
conducted by Pinhero et al, it was found that women who had a higher pre-pregnancy
BMI in addition to GDM had a much higher likelihood of having delayed breastfeeding
initiation compared to those mothers who had a normal pre-pregnancy BMI and GDM.
Additionally, a study by Haile et al looking at the relationship between GDM and
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exclusive breastfeeding at time of discharge found that women with a higher prepregnancy BMI compared to women with a normal pre-pregnancy BMI had lower odds
of exclusively breastfeeding at the time of discharge.27 This study also showed us that the
presence of GDM was negatively associated with higher a BMI.27 Together, these two
previous studies show that pre-pregnancy BMI should be considered as a potential
confounder in the present study.
Several studies have identified maternal characteristics such as younger maternal
age, low income, ethnicity, less maternal education, and unmarried status to be associated
with lower breastfeeding prevalence among women so these will all be taken into
consideration as confounders as well.40,41 Additionally, research studies conducted by
Ahluwalia et al indicated that women who had induced labor or cesarean sections were
less likely to initiate and continue breastfeeding compared to women who had
spontaneous vaginal deliveries.42,43 Due to this information we will also consider the
different types of delivery, vaginal vs cesarean, to be a confounders in our proposed
study.
In the proposed study, randomization will act to minimize any statistically
significant differences in baseline characteristics between the control and intervention
groups, which will serve to minimize the effects of confounding on the results.
Furthermore, we plan to collect and report these characteristics and will note any
significant differences in baseline characteristics between groups.
2.4 Safety
Metformin is a first-line, FDA approved drug for treating Type 2 diabetes.44 In
addition, it has been shown to be safe when used in women with polycystic ovary
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syndrome to improve insulin action.45 More recently studies have been conducted
showing that it is safe to use during lactation with milk concentrations being very low
and serum concentrations in breastfed infants being nearly undetectable.46 A large
prospective study by Glueck et al found that there were no adverse effects or differences
in growth and development between infants who were breastfed vs formula fed of
mothers that were taking metformin for 6 months postpartum.47 One of the most
concerning side effects of metformin is lactic acidosis. However, in a review of 18
clinical studies that looked at the use of metformin for treatment of polycystic ovary
syndrome there were not any reports of lactic acidosis occurring.45 All of this supports
the safety of metformin use in our study in both women with GDM and their infants and
we do not expect to see any negative effects on neonatal or maternal outcomes.
2.5 Review of Relevant Methodology
The purpose of this section is to review methodology in previous studies as they
pertain to the proposed study. A detailed description of the proposed study’s methods will
be discussed in Chapter 3.
2.5.1 Study Design
Most previous studies examining the effect of gestational diabetes on breastmilk
supply and lactation have been retrospective cohort studies, prospective cohort studies or
case-control studies.29,30,48 These designs of studies are limited since they can only
establish an association between GDM and low breastmilk supply, they can’t explain the
mechanism behind the outcome or establish direct correlation between metformin use
postpartum and breastfeeding in women with A2GDM during pregnancy. Thus, the
proposed study design is a randomized controlled trial, which allows us to determine a
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causal relationship between the intervention and the primary outcome while minimizing
the effect of bias and confounding variables.
Due to the nature of the intervention we will be able to blind the participants to
the group they are randomized to by giving the control group a placebo. In the
randomized controlled trial conducted by Nommsen-Rivers et al, the authors blinded the
members of the research team, as well as the statistician who reviewed the data that was
collected, to the allocation.49 We will similarly blind the research team members who
review the medical charts and data in order to reduce bias effect on the investigators’
interpretation of the results.
2.5.2 Selection Criteria
In order to select the inclusion and exclusion criteria for the proposed study, we
analyzed several previous studies’ selection criteria and chose the most applicable and
relevant to our study population.
First, our study will include only women with a diagnosis of GDM type A2
treated with metformin during pregnancy as this is the intended study population. We
differentiated type A1 from A2 because our study participants will have received treated
with metformin to control their blood glucose levels during the antenatal period. This
means that the participants will have GDM that didn’t respond to diet and exercise
changes alone and therefore need additional treatment with metformin. The gestational
age at time of recruitment in a previous randomized controlled trial was more than or
equal to 37 weeks’ gestation but in that study the intervention was started after birth.49
For the sake of our proposed study, we will only include term deliveries which means any
women who are over 37 weeks’ gestation and have a diagnosis of A2GDM on metformin
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will be recruited. The study will be introduced at the time of their diagnosis of GDM
requiring metformin for glycemic control during pregnancy, which could occur as early
as 24 weeks gestation. Consent and randomization will occur at the clinic once women
have reached 37 weeks’ gestation to ensure they were maintained on metformin for
glycemic control with their A2GDM diagnosis.
For our study, it is important to ensure that our group of women doesn’t have any
complicating comorbidities or prior diagnosis of diabetes that could alter our outcome
data. For similar reasons, Nommsen-Rivers et al excluded women who were diagnosed
pre-gestational Type 1 or Type 2 diabetes as well as those who had a history of breast
surgery and we will do the same in our study.49 Multiple gestation is defined as a highrisk pregnancy that increases the likelihood of GDM. Because of this, Nommsen-Rivers
et al excluded women with multiple gestation and we will also exclude women with
multiple gestations.
Furthermore, it is important to our study that participants are able to engage in
frequent and exclusive breastfeeding regardless of which group they are randomized to.
When conducting their study with breast pumping and breast emptying, Nommsen-Rivers
et al excluded women who would have insufficient frequency of completing both
pumping and emptying.49 In the proposed study, we will exclude women who do not plan
to exclusively breastfeed.
2.5.3 Intervention
In the previous RCT conducted by Nommsen-Rivers et al participants were
randomized 2:1 metformin:placebo allocation for the purpose of gathering more insight
into the tolerance and safety of metformin. For the purposes of our study we will be
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allocating participants in a 1:1 scheme. As was done in previous studies, we will be
encapsulating the metformin and the placebo into matching capsules and packages for the
purpose of maintaining blinding as best as we can. Unlike previous studies where the
intervention was started at the time of birth and given in accordance with a titration
schedule,49 our study will allow participants to remain on the same dose postpartum as
they were on in the antenatal period. To collect the data needed for the secondary
outcomes, participants will be given journals with specific forms to be filled out daily
over the course of the study.
2.5.4 Primary and Secondary Outcome Measures
A common problem encountered in studies on breastfeeding is how to quantify
the amount of breastmilk produced. The primary outcome for relevant studies is milk
output and this has been measured through weighing all milk that has been expressed and
collected over a 24 hour period.49 We felt that this data collection method was not
feasible for new mothers since it required extensive time and effort and therefore we
wouldn’t have good compliance among study participants. Instead, we plan to collect our
data using test weighs in which the participants will weight their infant on a specialized
scale provided to them immediately before and after each feeding. There have been many
studies conducted in the past that have concluded that test weighing is a reliable method
for assessing milk intake in infants 50-53 so we feel as though this will still provide us with
accurate data while making it as feasible as possible for our study participants.
Maternal fasting blood glucose levels and neonatal weights are often secondary
outcomes in previous studies examining the effect of metformin treatment in women with
GDM.13,16 Since metformin is known to adequately control blood glucose levels we will
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examine the mother’s glucose levels as a secondary outcome as well as trend the infant’s
weight over the course of the study. Additionally, since we are aiming to see an increase
in milk production with the use of metformin, we will monitor the number of wet diapers
produced daily by each infant as well as keep track of how much feeding
supplementation with formula is needed if the infant is unable to meet feeding
requirements with breastmilk alone.
2.5.5 Sample Size and Statistical Significance
Previous studies have estimated a post-intervention increase of 30% vs 0% in the
metformin vs placebo groups.49 The study conducted by Nommsen-Rivers et al is the
only randomized controlled trial we know of that has used metformin as an intervention
to increase breastmilk production but since their study was considered a pilot study this
affected their sample size parameters. They selected 79% power with an alpha of 0.10 to
detect a difference of 30% in the volume of breastmilk produced from women taking
metformin vs women taking the placebo.49 Additionally, they allocated participants 2:1
(metformin:placebo) and in our study we will be allocating 1:1. We will take this study’s
sample size calculation and estimation of effect size into consideration but due to the
nature of our study we will select a power of 80% with an alpha of 0.05.
2.6 Conclusion
The literature review supports the need for a well-designed randomized controlled
trial to determine the effect of metformin use during the postpartum period on breastmilk
supply in women diagnosed with GDM. There are very limited existing studies that look
at this relationship, especially with metformin use that continues from the third trimester
into the postpartum period. Existing studies have focused on the safety of metformin use
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as well as its efficacy in improving insulin sensitivity but its efficacy in improving milk
production has not been sufficiently studied and is still unknown. The results of a
randomized controlled trial could help to guide providers’ recommendations to women
diagnosed with GDM who are having difficulty with breastmilk supply and
breastfeeding.
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CHAPTER 3: STUDY METHODS
3.1 Study Design
We propose a two arm, double-blinded, parallel design, randomized controlled
trial analyzing the effect of metformin use during the first eight weeks of the post-partum
period on lactation in women who have been diagnosed with class A2 gestational
diabetes mellitus (GDM).
In this study, we plan to analyze the effects of metformin between two groups: the
experimental group of women who will take the prescribed dose of metformin daily and
the control group who will be receiving a placebo. Both groups will have received the
standard of care management for pregnant women diagnosed with A2 GDM during
pregnancy, including regular prenatal visits and metformin treatment which had been
started during their third trimester after failed management of gestational diabetes with
diet changes and exercise. The treatment with metformin will be continued for the
experimental group and will be substituted for a placebo at the time of delivery for the
control group. Patients and providers will be blinded as to which pill (placebo versus
metformin) they are receiving. We will use the Prenatal Breastfeeding Self-Efficacy
Scale (P-BSES) as an intake survey to characterize baseline breastfeeding confidence
between both groups of participants prior to being discharged from the hospital
(Appendix A). During the study, we will employ daily breastfeeding and pumping logs
amongst both groups as well as have mothers record their infants pre and post feeding
weights.
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3.2 Study Population and Sampling
The study population under investigation is women with singleton pregnancies in
the third trimester who are diagnosed with gestational diabetes mellitus. The study
population will be seeking prenatal care at the Yale New Haven Health System
(YNHHS), with selection for the study population derived from the pregnant women who
were diagnosed with GDM. The study population will include pregnant women over 18
years of age who were diagnosed with GDM and are being treated with metformin during
the antenatal period. We will recruit participants from Yale Maternal Fetal Medicine
Diabetes in Pregnancy Program at Long Wharf Medical Center which provides services
for pregnant women diagnosed with GDM.
Participants will be pregnant women who are (1) ≥18 years of age, (2) at 24–36
weeks of gestation, (3) have a singleton pregnancy, (4) are planning to exclusively
breastfeed their infant, (5) were able to read the information sheet and sign the consent
form and (6) are planning to deliver within the Yale New Haven Health System. Prior to
the study, women will be excluded from the study based on the following: (1) any of the
following pre-existing health conditions as indicated in medical records: pre-gestational
diabetes, chronic kidney disease, chronic liver disease including hepatitis, chronic
hypertension on medication other than aspirin, and lupus (2) those who have had breast
surgery (including single or double mastectomy and/or breast implants) (3) mothers with
pre-gestational diabetes and (4) mothers diagnosed with gestational diabetes prior to 24
weeks’ gestation.
Inclusion Criteria
•

Exclusion Criteria
•

Age ≥18 years old
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Maternal health complications:

•
•
•
•

At 24-36 weeks of gestation
Singleton pregnancy
Will exclusively breastfeed infant
Will deliver within the Yale New
Haven Health System
•
•
•

1. Pre-gestational diabetes
2. Chronic kidney disease
3. Chronic liver disease
including hepatitis
4. Chronic hypertension
5. Lupus
Not planning on exclusively
breastfeeding
Previous single or double
mastectomy and/or breast implants
Gestational diabetes diagnosis
before 24 weeks’ gestation

Table 1: Inclusion and Exclusion Criteria
3.3 Recruitment
Women who visit the Yale Maternal Fetal Medicine Diabetes in Pregnancy
Program and are diagnosed with GDM and initiating treatment with metformin during the
third trimester will be recruited for our study. We will exclude women who do not plan to
deliver at YNHHS, as we will not have access to their delivery records. We plan to
recruit women at their routine prenatal care visits occurring during the third trimester. If
the woman has GDM at a prenatal visit and satisfies the remaining inclusion criteria, the
patient will be informed of the study and consented by the research coordinator.
Women who would like to complete the study will read and sign the consent form
(appendix B) to provide their informed, written consent to study participation. Once
informed consent is obtained, women will be randomized in a 1:1 enrollment ratio to
either the metformin group or the placebo group using an online randomization software
and a block randomization scheme. Randomization will take place at the end of their
third trimester (>37 weeks’ gestation) in order to ensure medication continuation
immediately after delivery and to ensure women did not get changed to another
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medication from metformin during their prenatal care to help control their gestational
diabetes.
After delivery all women in the trial will receive their medication through the
investigational pharmacy, which will dispense metformin or a placebo pill designed to
appear like metformin. The women will be instructed to not take any remaining pills of
their own metformin following delivery. Both groups will take the pills for 8 weeks
following delivery. The dosage of metformin will be 500mg daily.
The total recruitment period will be 12 months, from August 1, 2020 to August 1,
2021. The follow-up period will extend 8 weeks after each woman’s date of delivery.
3.4 Subject Protection and Confidentiality
The Yale Institutional Review Board policy on research involving pregnant
women and neonates is referenced in the consent form in Appendix B. The study will be
conducted pending ethical review by the Human Investigation Committee (HIC) of Yale
University School of Medicine and YNHHS. Written informed consent will be obtained
from all participants prior to entry into the study at the patient’s prenatal visit during the
third trimester (see Appendix B). Subjects under the age of 18 years-old will not be
included in this study. Additionally, all research staff will be trained in HIPAA. Upon
entry into the study, participants will receive a de-identified number for data collection
and statistical analysis. All protected health information will be de-identified for the
purposes of blinding and confidentiality in the data analysis phase of the study. A Yaleencrypted computer with a password-protected Excel-based database will be used to
maintain confidentiality and security of the data. Only co-investigators will have the
password and access to the database. All backup drives will be password-protected. The
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database will only be accessed on hospital property or through secure VPN access. All
associated paperwork will be stored in a locked file in a locked office.
3.5 Study Variables and Measures
3.5.1 Independent Variable
The independent variable in this study is metformin use during the postpartum
period, which is operationalized in the experimental group by having participants receive
metformin from the investigational drug pharmacy after delivery. The control group will
be given a placebo tablet from the same pharmacy to take once daily starting at the time
of delivery. The pills will be identical in appearance so patients and their providers are
blinded to which group they are in. Participants will be asked to maintain a log of their
medication compliance as well as make note of any side effects they might be
experiencing. Participants will be given all doses of their medication upon discharge from
the hospital (56 total pills). Will contact participants once per week to review their logs,
discuss any questions and obtain a pill count to monitor compliance.
3.5.2 Study Outcomes
The primary outcome of this study is breastmilk production. This will be
measured using infant test weighs taken immediately before and after each feeding. We
will ask participants to log these results in their breastfeeding logs which will be provided
to them (Appendix C). Specialized scales will be provided for each participant to take
home and use for the duration of the study to weight their infants. Prior to discharge from
the hospital each mother will have the opportunity to meet with a lactation specialist to
ensure that she is prepared and feels confident in her abilities to breastfeed once she
returns home. Additionally, we will instruct the participants on how to get accurate
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weights and observe them conducting practice test weighs prior to discharge. Should they
get home and have any questions we will provide them with a link to an instructional
video of how to conduct these weighs. Each participant will receive a follow up calls
once a week throughout the duration of the study in which they can ask any questions or
concerns they might have, and we will ensure that they are properly conducting the test
weighs.
There are five secondary outcomes of interest that we will analyze: (1) onset of
lactogenesis (2) infant weights at their routine pediatrician visits, (3) the need for feeding
supplementation with formula, (4) number of wet diapers per day, and (5) maternal
fasting glucose levels tested daily. Infant weights will also be checked at each follow up
appointment which will occur at weeks 1,2, 4, and 8 of the study. We will ask each study
participant to record the number of wet diapers and times that supplementation with
formula was needed daily in the same log that they will be using to record their breast
feedings (Appendix C). Participants will be instructed to take their own fasting blood
glucose levels once daily upon waking in the morning for the day, prior to their first meal
and keep a log of their results which will then be collected at the conclusion of the study.
(Appendix D)
Primary Outcome
• Breastmilk production as
measured by pre and post feeding
infant weights.

Secondary Outcomes
• Time of onset of lactogenesis
• Infant weights at their pediatrician
visits
• Frequency of feeding
supplementation with formula
• Number of wet diapers daily
• Maternal fasting glucose levels

Table 2: Outcomes
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3.5.3 Potential Confounding and Explanatory Variables
Development of GDM and subsequent low breastmilk supply is influenced by
several covariates. Potential confounders include maternal age, maternal ethnicity,
maternal education level achieved, maternal marital status, pre-pregnancy BMI, family
history of GDM or type 2 diabetes, diagnosis of GDM in previous pregnancies, other
signs of insulin resistance such as polycystic ovarian syndrome, number of previous
breastfed infants, vaginal versus cesarean delivery, and parity. As participants will be
randomized to their assigned group, we hope to minimize the effect of cofounding
variables on the main outcome. We will also obtain this demographic and medical history
data via an intake survey upon entry into the study (Appendix E) and through the
participants’ charts and will compare these characteristics of the participants between
assigned groups for any significant differences.
3.6 Data Collection
Upon entry into the study, each participant will complete a Prenatal Breastfeeding
Self-Efficacy Scale (P-BSES) to characterize their baseline breastfeeding confidence
prior to being discharged from the hospital. Those who score less than 60 points on the
scale or those who do not feel confident or adequately prepared will have an additional
lactation consultation prior to discharge. The P-BSES is a 20-item scale designed to
measure pregnant women’s self-efficacy for breastfeeding. The four factors comprising
the scale assess confidence regarding 1) skills and demands for breastfeeding or
pumping, 2) gathering information about breastfeeding, 3) breastfeeding around other
people, and 4) social pressure when breastfeeding. There is evidence that the P-BSES has
good content validity and internal consistency1 (Refer to Appendix A). We will obtain
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previous breastfeeding information and maternal education level from each participant
using a questionnaire (Appendix E). Information on baseline characteristics, including
maternal age, maternal ethnicity, pre-pregnancy weight, height, and BMI will all be
obtained from participant’s electronic medical records.
In both groups, we will have participants log their daily feedings in a journal that
will be given to them (Refer to Appendix C). This journal will also be used to input the
test weighs before and after each feeding. We will ask participants to record the time of
feeding, the duration of the feed, the type of feeding and if supplementation with formula
was used. Additionally, we will have participants log the number of wet diapers per day.
We will be evaluating the mother’s fasting blood glucose levels daily so we will ask the
participants to take a fasting blood glucose every morning and to record these results
(Appendix D).
After discharge from delivery, we will ask to have the participants follow up at
the Yale Pediatrics office at weeks 1, 2, 4, and 8. During these appointments we will
perform all standard neonatal care as well as review the participant’s journal entries and
record the infant’s weight.
3.7 Sample Size Calculation
The main goal of the proposed study is to test the two-sided null hypothesis that
metformin use during the postpartum period does not change the amount of breastmilk
production. Sample size calculation is based on the primary outcome of breastmilk
production. The aim is to observe an increase in the amount of breastmilk produced in the
experimental group compared to the control group. Our calculation is based on previous
studies which found there to be a median increase of 8mL/24hr. For a two-sided
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hypothesis with a type 1 error of 1% and a power of 80%, a total sample size of 56 is
required, or 28 in each arm. Due to the nature of the study and comparing median values
versus means, we will add 15% to each group to compensate. Additionally, we must
account for 10% attrition rate. Therefore, our final sample size of will be 72 participants
used in this study. Please see Appendix F for the full sample size calculation.
3.8 Statistical Analysis
Demographic information will be obtained for all participating women and will be
analyzed for any statistically significant differences between groups (Refer to Table 3).
Characteristics of interest that will be analyzed include maternal age, maternal ethnicity,
maternal education level achieved, maternal marital status, pre-pregnancy BMI, family
history of GDM or type 2 diabetes, diagnosis of GDM in previous pregnancies, other
signs of insulin resistance such as polycystic ovarian syndrome, number of previous
breastfed infants, vaginal versus cesarean delivery, and parity. Student t-test will be used
for analysis of maternal age, as a continuous, parametric variable. Wilcoxon rank sum
will be used to analyze ordinal variables such as maternal ethnicity, maternal marital
status, and maternal BMI, as well as non-parametric continuous variables such as parity.
A chi square test will be used to analyze proportions between groups for ethnicity and
previous diagnosis of GDM. Lastly, we will analyze educational level (measured by
mean years) with ANOVA. Multivariate analysis using logistic regression will be utilized
for any statistically significant differences between groups in these baseline
characteristics.
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Baseline Characteristics

Metformin
Group %

Maternal Age
18-24 years
25-30 years
30-35 years
≥35 years
Ethnicity
Non-Hispanic White
Black
Hispanic
Asian
Other
Marital Status
Married
Single
Other Forms of Insulin
Resistance
Yes
No
Family History of GDM
Yes
No
Family History of Type 2 DM
Yes
No
Diagnosis of GDM in
Previous Pregnancy
Yes
No
Parity
0
1
2
>3
Number of Previous
Breastfed Infants
0
1
2
>3
Type of Delivery
Vaginal
Cesarean
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Placebo
group %

P-value
(P<0.05)

Pre-pregnancy BMI
19.8-25.9
26.0-28.9
29.0-34.9
≥35.0
Mean (SD)

Mean (SD)

Education (years)
Table 3: Baseline Characteristics of Study Population
3.9 Timeline and Resources
Pending Institutional Review Board (IRB) approval, we will begin recruiting
pregnant women for 12 months; all mothers must deliver within the first 18 months and
follow up will last for 2 months following time of delivery. All data will be collected
within a 2-year timespan. We will then require one month to run and interpret results and
an additional month to write and report our findings. Proposed study personnel include:
one principal investigator to oversee all operations, one physician trained in obstetrics to
assess participant’s charts for diagnosis of A2GDM, one Physician Assistant student for
data organization, statistical analysis and writing, and one trained research assistant for
recruitment and intake.
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CHAPTER 4: CONCLUSION
4.1 Advantages and Disadvantages
It is well documented that women who are diagnosed with gestational diabetes
mellitus have worse breastfeeding outcomes than their counterparts. Specifically, women
with GDM have much lower exclusive breastfeeding rates and shorter durations of
breastfeeding.1,2 Unfortunately, up to this point there have not been any studies looking at
effective interventions to improve breastfeeding rates in this population. Therefore, there
is a need for a large randomized controlled trial to examine the use of an existing
therapeutic agent used in treating gestational diabetes and determine if there is a causal
relationship between metformin use during the postpartum period and increased
breastmilk supply. This study addresses the paucity in the current literature and has the
potential to change current practice guidelines.

The proposed study has both its strengths and limitations. A major strength of our
study is its feasibility and practicality. The intervention requires little time commitment
from participants and is easy to implement. Metformin, in comparison to insulin, has
been found to be viewed favorably by patients due to its oral route of administration, low
cost, easy dose titration, and low risk of hypoglycemia.3 Also, study participants will
have been on metformin prior to delivery so they will already be used to the medication
and will be less likely to experience side effects throughout the duration of the study. All
of these are factors that will aid in achieving high medication compliance with
participants. Additionally, the intervention is low-cost since all required medications and
devices will be supplied to each participant. We will be able to closely monitor adherence
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as follow-up visits will be completed at set time intervals and phone call follow-ups will
be implemented weekly throughout the duration of the study to answer any questions or
concerns participants might have. Therefore, we anticipate strong internal validity and
minimal response bias in this study. However, by limiting our study to the Yale New
Haven Health System we may limit our external validity and generalizability. Despite
limiting recruitment to the Yale New Haven Health System, we will strive to recruit a
diverse group of participants.

The main advantage of this study is its randomized, prospective design that allows
for the observation of a causal relationship between metformin treatment and breastmilk
production in women diagnosed with GDM. It is the only randomized controlled trial that
tests the effect of continuing metformin treatment into the postpartum period on the
production of breastmilk in women with a diagnosis of GDM. By conducting an RCT and
randomizing patients 1:1 to the intervention and control groups, we hope to decrease
selection bias and confounders. Furthermore, our proposed study will be double blinded
which we hope will aid in limiting outcome reporting bias.

When considering the timeline for the study we realize that an eight-weeklong
duration may limit our understanding of long-term effects of metformin on breast milk
production. However, we feel that a longer intervention duration would decrease patient
adherence. Since we know that metformin typically begins to improve blood sugar
control within a week3,4 we feel as though eight weeks is a sufficient amount of time to
get an understanding of what effects metformin might have. We know that studies similar
to ours that have been done in the past have concluded after about four weeks5 so we
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hope that continuing our study for an additional four weeks will be an advantage and give
additional insight into our research question and place emphasis on the importance of
continued breastfeeding beyond the initial postpartum period.

4.2 Clinical and Public Health Significance
In all of the previous studies addressing the different therapeutic options for
diabetes during pregnancy, several neonatal and maternal outcomes have been analyzed
and studied but one factor that hasn’t been studied in depth is the effect on breast milk
production and lactogenesis. This is a long-term factor that can have an impact on
infancy and childhood for many neonates and it is an important factor to identify and
study in correlation with metformin therapy.
This is an important problem to find a solution to because currently 23% of
reproductive aged women in the United States are prediabetic and 8.2% of women are
diagnosed with gestational diabetes; therefore, this could be an unrealized impediment to
raising breastfeeding rates and breastfeeding duration in the US.6 Finding a way to
increase the postpartum milk production in women diagnosed with GDM could aid in
longer compliance with breastfeeding. This is important because it has been proven that
continued breastfeeding for more than six months lowers the chances of childhood and
adult illnesses and, if the child does get ill, can help the child in recovering more
quickly.7 It has also been shown that longer breastfeeding duration lessens the child’s
chances of developing type 1 and type 2 diabetes as well as obesity.8 Breastfeeding is not
only beneficial for infants but also for mothers, by continuing breastfeeding beyond six
months, it can lower the lifelong risk of developing heart disease,9 type 2 diabetes10 and
cancers of the breast, ovaries and uterus in women.11 It is clear that it is important to try
44

to find a targeted therapy that can support lactation success in women who have glucose
intolerance.
Our hope is that this proposed study would address an important question that has
not yet been addressed in the literature. The findings of this study will provide insight
into breastfeeding rates and success in women with A2GDM.
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Appendices
Appendix A: Infant Feeding Intentions Scale
Please read the following statements and answer circling the number closest to your
feelings. It is important to know (remember) that there is no right or wrong answer
in answering these questions. We are interested in how much you are relyed of
yourself about your breastfeeding.
1: I am definitely not confident 2: I am not quite confident 3: I am confident4: I am very confident 5:
I am completely confident
1. I can find the answers to problems I may encounter while
breastfeeding my baby.
2. I can find the information I need about breastfeeding my
baby.
3. If I have questions about breastfeeding my baby, I know
whom I can ask.
4. I can talk about the importance of breastfeeding my baby
with my husband.
5. I can talk about breastfeeding my baby with health workers.
6. I can organize my day according to the times I need to
breastfeed my baby.
7. I can find time for breastfeeding my baby even if I am busy.
8. I can breastfeed my baby even when I am tired.
9. I can breastfeed my baby even when I am feeling
depressed.
10. I can draw milk manually or through use of a breast pump.
11. I can milk my breast and prepare my milk for someone else
to feed my baby.

1 2 3 4

5

1 2 3 4

5

1 2 3 4

5

1 2 3 4

5

1 2 3 4
1 2 3 4

5
5

1 2 3 4
1 2 3 4
1 2 3 4

5
5
5

1 2 3 4
1 2 3 4

5
5

12.
13.
14.
15.
16.

1
1
1
1
1

4
4
4
4
4

5
5
5
5
5

1 2 3 4

5

1 2 3 4

5

1 2 3 4

5

1 2 3 4

5

17.
18.
19.
20.

I can breastfeed my baby even if it causes a little discomfort.
I can breastfeed my baby without any feelings of shame.
I can breastfeed my baby while my husband is present.
I can breastfeed my baby while my family or friends are present.
I can breastfeed my baby even when people I do not know are
present.
I can call a breastfeeding consultant when I have problems with
breastfeeding.
I would breastfeed my baby even if my husband did not want me
to do it.
I would breastfeed my baby even my family did not want me to
do it.
I can breastfeed my baby for two years.
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2
2
2
2
2

3
3
3
3
3

Appendix B: Human Investigations Committee Consent Form
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN
HOSPITAL
Study Title: Randomized Study of Postpartum Metformin Use to Augment Breastmilk
Supply
Principal Investigator: Audrey Merriam, MD
Co-Principal Investigator: Meghan Sowers, PA-SII
Invitation to Participate and Description of Project
You are invited to participate in a research study designed to look at the effects of
continuing metformin treatment into the postpartum period and its effects on breastmilk
supply in women with gestational diabetes. If you are reading this consent form, you have
been selected for recruitment in this study during your pregnancy. You were selected for
potential recruitment in this study, because you are currently pregnant and have gestational
diabetes mellitus which is currently being treated with metformin. Gestational diabetes is
a condition that only affects pregnant women and causes high blood sugar levels. This
condition can have many effects on mothers and babies, one of them being delayed
lactogenesis, when milk production starts, as well as decreased milk production resulting
in lower breastfeeding rates. This study will take place within the Yale New Haven Health
System over the next two years.
In order to decide whether or not you wish to be a part of this research study, you should
know enough about its risks and benefits to make an informed decision. This consent form
gives you detailed information about the research study, which a member of the research
team will discuss with you. This discussion should go over all aspects of this research: its
purpose, the procedures that will be performed, any risks of the procedures, possible
benefits and possible alternative treatments. Once you understand the study, you will be
asked if you wish to participate; if so, you will be asked to sign this form.
Description of Procedures
If you agree to participate in this study, you will be randomly assigned to one of two
groups, either the metformin group or the placebo group. An online software will be used
to assign all participants randomly into one of the two groups.
If you are assigned to the metformin group, you will be instructed to take metformin
daily. This will start at the time of delivery and will continue for eight weeks postpartum.
You will also be given a journal to record your feedings as well as other variables that we
would like to collect data on. Additionally, we will ask participants to check their blood
sugar levels daily and record these findings.

48

If you are assigned to the placebo group, you will be instructed to take one placebo tablet
daily. This will start at the time of delivery and will continue for eight weeks postpartum.
You will also be given a journal to record your feedings as well as other variables that we
would like to collect data on. Additionally, we will ask participants to check their blood
sugar levels daily and record these findings.
After you give birth, our research team will contact you and give you instructions as to
what to do going forward. We will additionally gather data from your medical chart such
as demographic information (i.e. age, race), past medical history (e.g. number of previous
pregnancies, health complications) weight, gestational age at delivery, whether or not you
had a Cesarean section (and if so, why), assessment of your baby, and any complications
that may have occurred during labor or birth. This information will help us determine if
there is any difference in outcomes between the groups.
You will be told of any significant new findings that develop during the course of your
participation in this study that may affect your willingness to continue to participate.
Risks and Inconveniences

Confidentiality
Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or State
law. Examples of information that we are legally required to disclose include abuse of a
child or elderly person, or certain reportable diseases. When the results of the research are
published or discussed in conferences, no information will be included that would reveal
your identity unless your specific consent for this activity is obtained.
Representatives from the Yale Human Research Protection Program, the Yale Human
Investigation Committee (the committee that reviews, approves, and monitors research on
human subjects) may inspect study records during internal auditing procedures. However,
these individuals are required to keep all information confidential.
Voluntary Participation and Withdrawal
Participating in this study is voluntary. You are free to choose not to take part in this
study. Refusing to participate will involve no penalty or loss of benefits to which you are
otherwise entitled (such as your healthcare outside of the study, the payment for your
healthcare, or your healthcare benefits). However, you will not be able to enroll in this
research study and will not receive study procedures as a study participant if you do not
allow use of your information as part of this study. If you do become a subject, you are
free to stop and withdraw from this study at any time during its course.
To withdraw from the study, you can call a member of the research team at any time and
tell them that you no longer want to take part. The researchers may withdraw you from
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participating in the research if necessary. This may occur if your obstetrician feels it is
medically unsafe to proceed with the intervention to which you have been allocated.
Withdrawing from the study will involve no penalty or loss of benefits to which you are
otherwise entitled. It will not harm your relationship with your own doctors.
When you withdraw from the study, no new health information identifying you will be
gathered after that date. Information that has already been gathered may still be used and
given to others until the end of the research study, as necessary to ensure the integrity of
the study and/or study oversight.
You do not give up any of your legal rights by signing this form.
Questions
We have used some technical terms in this form. Please feel free to ask about anything
you don't understand and to consider this research and the consent form carefully – as long
as you feel is necessary – before you make a decision.
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Authorization
I have read (or someone has read to me) this form and have decided to participate in the
project described above. Its general purposes, the particulars of my involvement and
possible hazards and inconveniences have been explained to my satisfaction. My signature
also indicates that I have received a copy of this consent form.

Name of Subject:_____________________________

Signature:___________________________________
Relationship:________________________________
Date:______________________________________

___________________________________________
Signature of Principal Investigator

___________________
Date

or
___________________________________________
Signature of Person Obtaining Consent

___________________
Date

If you have further questions about this project or if you have a research-related problem,
you may contact the Principal Investigator, Dr. Audrey Merriam. If, after you have
signed this form you have any questions about your privacy rights, please contact the
Yale Privacy Officer at 203-432-5919. If you would like to talk with someone other than
the researchers to discuss problems, concerns, and questions you may have concerning
this research, or to discuss your rights as a research subject, you may contact the Yale
Human Investigation Committee at (203) 785-4688.
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Appendix C: Breastfeeding Log

Date

Start Stop
Time Time

Weight Weight Breast Was Supplementation Number Notes
before
after
(Left
a
with Formula?
of Wet
feeding feeding
or
bottle
How much?
Diapers
(in g)
(in g) Right) used?
Y or
N

52

Appendix D: Maternal Blood Glucose Monitoring Log
Day/Date

Time

Fasting? Y or N

Blood Sugar
Reading
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Did you take
your
medication
today? Y or N

Notes

Appendix E: Baseline Intake Form

Patient Information Form
Please fill out this form to the best of your ability.
1. What is your marital status? (Circle one)
Married

Single

2. Do you have a family history of gestational diabetes mellitus?
3. Do you have a family history of type 2 diabetes?
4. Have you ever been pregnant before?

Yes

Yes

Yes

No

No

No

a. If “yes” how many times? _________
b. If “yes” were you ever diagnosed with gestational diabetes during any of
your previous pregnancies? Yes

No

c. If “yes” did you breastfeed? Yes

No

5. Approximately how many years did you attend school (including high school,
college, graduate school, or an additional education)? ______
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Appendix F: Sample Size Calculation
Input: Tail(s): Two
Power, 1 - β = 0.80
Type I error rate, α = 1%
Median increase in primary outcome, 8mL/24hr
Sample Size: 56 (28 per group)
Compensation for comparing medians, 15% to each group, 56 x 1.15=64.4 participants
Estimated attrition rate, 10%, 65 x 1.10= 71.5 participants
Adjusted Sample Size = 72 participants (36 per group)
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